This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.
The treatment period was followed by a follow-up period starting the day after the last intake of study medication, regardless of the actual duration of study drug administration and ended on Day 90 (+ 7 days). Participants who did not complete the treatment period also entered the follow-up period. It was also possible that participants did not enter the follow-up period, e.g. due to withdrawal of consent or termination of study participation. Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.
Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
Avellaneda, Buenos Aires, Argentina
San Miguel, Buenos Aires, Argentina
Tres de Febrero, Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Vicente López, Argentina